

Microsoft Bing

Therapeutic Resistance in PDAC: Current Challenges and Future Op...

Sign in

ALL IMAGES VIDEOS

2,040,000 Results Any time

Pancreatic Cancer: Current Progress and Future Challenges
www.ijbs.com/v12p0270.htm
Feb 03, 2016 - Therapeutic resistance is one of the major challenges in improving disease outcome in pancreatic cancer. Chand and colleagues discussed the potential mechanisms of therapeutic resistance in their article entitled "The landscape of..."
Cited by: 19 Author: S. Perwez Hussain
Publish Year: 2016

Therapeutic developments in pancreatic cancer: current and ...
<https://pubmed.ncbi.nlm.nih.gov/29717230>
The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next...
Cited by: 299 Author: John P. Neoptolemos, Jörg Kleeff, Jörg Kl...
Publish Year: 2018

PEOPLE ALSO ASK

What are the challenges and opportunities in cancer drug resistance?

Search Tools
Turn off Hover Translation (关闭翻译)

激活 Windows
转到设置以激活 Windows。

548,000 Results

Any time ▾

Pancreatic Cancer: Current Progress and Future Challenges ...

europepmc.org/articles/PMC4753155

Therapeutic resistance is one of the major challenges in improving disease outcome in **pancreatic cancer**. Chand and colleagues discussed the potential mechanisms of **therapeutic resistance** in their article entitled "The landscape of **pancreatic cancer therapeutic resistance** mechanisms" 7 and highlighted the potential targets to overcome the highly stubborn resistance and enhance drug efficacy in **pancreatic cancer**.

Cited by: 20

Author: S. Pervez Hussain

Publish Year: 2016

Pancreatic Cancer: Current Progress and Future Challenges

<https://www.ijbs.com/v12p0270.htm> ▾

Feb 03, 2016 · Therapeutic resistance is one of the major challenges in improving disease outcome in **pancreatic cancer**. Chand and colleagues discussed the potential mechanisms of **therapeutic resistance** in their article entitled "The landscape of **pancreatic cancer therapeutic resistance** mechanisms" (7) and highlighted the potential targets to overcome the highly stubborn resistance and enhance drug efficacy in **pancreatic cancer**.

[PDF] Pancreatic Cancer: Current Progress and Future Challenges

www.ijbs.com/v12p0270.pdf

lection of articles key issues have been discussed to understand, combat and ultimately defeat this lethal malignancy with focus on the **current** progress and **future challenges** to improve early detection and treatment strategies. **Therapeutic resistance** is one of the major chal-lenges in improving disease

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 65602

Manuscript Type: REVIEW

Therapeutic Resistance in PDAC: Current Challenges and Future Opportunities

PDAC: Current therapies and future opportunities

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the USA. Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX significantly improve patient survival, the prevalence of therapy resistance remains a major roadblock in the success of these agents. This review discusses the molecular mechanisms that play a crucial role in PDAC therapy resistance and how a better understanding of these mechanisms has shaped clinical trials for pancreatic cancer chemotherapy. Specifically, we have discussed the metabolic

Match Overview

Match #	Source	Words	Crawled	Similarity
1	Internet	29 words	28-Jun-2020 www.nature.com	1%
2	Crossref	27 words	Luisa Finkbeiner, Johane Gout, Etienne Roger, Fernando Ku de de Almeida et al. "DNA damage repair as a target in pe...	<1%
3	Internet	27 words	18-Jul-2021 www.frontiersin.org	<1%
4	Internet	17 words	07-Nov-2020 cancerandmetabolism.biomedcentral.com	<1%
5	Internet	17 words	20-Jul-2020 www.oncotarget.com	<1%
6	Internet	16 words	25-Mar-2021 www.abcam.com	<1%
7	Internet	15 words	12-Sep-2020 ro-journal.biomedcentral.com	<1%
8	Internet	15 words	29-Mar-2020 www.science.gov	<1%

国内版

国际版

Therapeutic resistance in pancreatic ductal adenocarcinoma: Curre



ALL

IMAGES

VIDEOS

102,000 Results

Any time ▾

[Gemcitabine resistance in pancreatic ductal adenocarcinoma](#)

<https://pubmed.ncbi.nlm.nih.gov/26690340>

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The disappointing 5-year survival rate of below 5% stems from drug **resistance** to all known therapies, as well as from disease presentation at a late stage when PDA is already metastatic. Gemcitabine has been the corners ...

Cited by: 170

Author: Yoav Binenbaum, Shorook Na'ara, Ziv Gil

Publish Year: 2015

[Pancreatic Ductal Adenocarcinoma: Biological Hallmarks ...](#)

<https://pubmed.ncbi.nlm.nih.gov/31395068>

Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with poor prognosis and rising incidence. Late detection and a particularly aggressive biology are the major **challenges** which determine **therapeutic** failure. In this review, we present the **current** status and the recent advances i ...

Cited by: 117

Author: Michael Orth, Michael Orth, Philipp Metz...

Publish Year: 2019

[Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311973>

Jun 08, 2020 · Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies due to the rapid rate of metastasis and high **resistance** to currently applied cancer therapies. The complex mechanism underlying the development and progression of PDAC includes interactions between genomic, epigenomic, and signaling pathway alterations.

Cited by: 4

Author: Sona Ciernikova, Julie Earl, María Laura ...

Publish Year: 2020

[Therapeutic developments in pancreatic cancer: current and ...](#)

<https://www.nature.com/articles/s41575-018-0005-x>

May 01, 2018 · The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second ...

Cited by: 354

Author: John P. Neoptolemos, Jörg Kleeff, Jörg Kl...

Publish Year: 2018